AP2011006034A0 - Substituted triazole and imidazole derivatives as gamma secretase modulators. - Google Patents

Substituted triazole and imidazole derivatives as gamma secretase modulators.

Info

Publication number
AP2011006034A0
AP2011006034A0 AP2011006034A AP2011006034A AP2011006034A0 AP 2011006034 A0 AP2011006034 A0 AP 2011006034A0 AP 2011006034 A AP2011006034 A AP 2011006034A AP 2011006034 A AP2011006034 A AP 2011006034A AP 2011006034 A0 AP2011006034 A0 AP 2011006034A0
Authority
AP
ARIPO
Prior art keywords
imidazole derivatives
gamma secretase
substituted triazole
secretase modulators
modulators
Prior art date
Application number
AP2011006034A
Other languages
English (en)
Inventor
Daniel Oehlrich
Tongfei Wu
Henricus Jacobus Maria Gijsen
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AP2011006034A0 publication Critical patent/AP2011006034A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2011006034A 2009-07-15 2010-07-13 Substituted triazole and imidazole derivatives as gamma secretase modulators. AP2011006034A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09165585 2009-07-15
EP10164625 2010-06-01
PCT/EP2010/060083 WO2011006903A1 (en) 2009-07-15 2010-07-13 Substituted triazole and imidazole derivatives as gamma secretase modulators

Publications (1)

Publication Number Publication Date
AP2011006034A0 true AP2011006034A0 (en) 2011-12-31

Family

ID=42542935

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011006034A AP2011006034A0 (en) 2009-07-15 2010-07-13 Substituted triazole and imidazole derivatives as gamma secretase modulators.

Country Status (18)

Country Link
US (1) US8946266B2 (xx)
EP (1) EP2454239B1 (xx)
JP (2) JP2012532912A (xx)
KR (1) KR20120050450A (xx)
CN (1) CN102482227A (xx)
AP (1) AP2011006034A0 (xx)
AU (1) AU2010272578B2 (xx)
BR (1) BR112012000915A2 (xx)
CA (1) CA2778517A1 (xx)
EA (1) EA021047B1 (xx)
ES (1) ES2519565T3 (xx)
IL (1) IL217491A (xx)
MX (1) MX2012000763A (xx)
NZ (1) NZ597505A (xx)
SG (1) SG177644A1 (xx)
TW (1) TW201109316A (xx)
WO (1) WO2011006903A1 (xx)
ZA (1) ZA201200285B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453000B2 (en) * 2007-08-31 2016-09-27 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
MX2011008335A (es) 2009-02-06 2011-09-06 Ortho Mcneil Janssen Pharm Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa.
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
US8754100B2 (en) 2009-02-26 2014-06-17 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP5580816B2 (ja) 2009-02-26 2014-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロトリアゾロピリジン誘導体の塩およびその結晶
WO2010145883A1 (en) 2009-05-07 2010-12-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
CA2778517A1 (en) 2009-07-15 2011-01-20 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
KR20120123677A (ko) 2010-01-15 2012-11-09 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 트리아졸 유도체
US8822699B2 (en) 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CN102690194B (zh) * 2011-03-24 2014-06-25 上海通远生物科技有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
BR112013023984A2 (pt) * 2011-03-24 2016-09-13 Cellzome Ltd derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase
WO2013005354A1 (ja) * 2011-07-01 2013-01-10 武田薬品工業株式会社 複素環化合物
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
EP2731968A1 (en) 2011-07-15 2014-05-21 Janssen Pharmaceutica NV Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof
EP2817310B1 (en) * 2012-02-21 2018-03-21 Merck Patent GmbH 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
MX355164B (es) 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
HUE040025T2 (hu) * 2012-08-24 2019-02-28 Univ Texas A HIF aktivitás heterociklusos modulátorai betegség kezelésére
JP6275161B2 (ja) * 2012-12-20 2018-02-07 ヤンセン ファーマシューティカ エヌ.ベー. γセクレターゼ調節剤としての新規な三環式3,4−ジヒドロ−2H−ピリド[1,2−a]ピラジン−1,6−ジオン誘導体
JP6283691B2 (ja) 2013-01-17 2018-02-21 ヤンセン ファーマシューティカ エヌ.ベー. γセクレターゼ調節剤としての新規な置換ピリド−ピペラジノン誘導体
WO2014195322A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
CN105308037B (zh) 2013-06-04 2017-09-19 阿克图拉姆生命科学股份公司 三唑化合物及其作为γ分泌酶调节剂的用途
EP3004079B1 (en) 2013-06-04 2018-01-17 Acturum Real Estate AB Pyrimidine compounds and their use as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3110420B8 (en) 2014-02-25 2019-07-10 Board of Regents, The University of Texas System Salts of heterocyclic modulators of hif activity for treatment of disease
EP3212633B1 (en) 2014-10-31 2019-12-04 The General Hospital Corporation Potent gamma-secretase modulators
ES2796276T3 (es) * 2015-02-05 2020-11-26 Ab Science Compuestos con actividad antitumoral
WO2018011164A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
JP7132218B2 (ja) * 2016-11-08 2022-09-06 エフ.ホフマン-ラ ロシュ アーゲー フェノキシトリアゾール
PE20211246A1 (es) 2017-10-11 2021-07-13 Hoffmann La Roche Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
KR20220035939A (ko) 2019-07-22 2022-03-22 바이엘 악티엔게젤샤프트 살충제로서의 5-아미노-치환된 피라졸 및 트리아졸
CN110759902B (zh) * 2019-11-01 2022-04-22 海南一龄医疗产业发展有限公司 Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途
WO2022033991A1 (de) 2020-08-13 2022-02-17 Bayer Aktiengesellschaft 5-amino substituierte triazole als schädlingsbekämpfungsmittel
CN112480073B (zh) * 2020-12-02 2022-03-22 武汉药明康德新药开发有限公司 1-烷基-3,5-芳基取代的1,2,4三氮唑化合物的合成方法
WO2023238065A1 (en) 2022-06-09 2023-12-14 Glaxosmithkline Intellectual Property Development Limited Nitrogen containing condensed 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO1997003067A1 (en) 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
KR20010100977A (ko) * 1998-11-03 2001-11-14 스타르크, 카르크 치환된 2-페닐벤즈이미다졸, 그의 제조 및 그의 용도
PT1192131E (pt) 1999-06-10 2004-11-30 Warner Lambert Co Metodo para inibicao da agergacao de proteinas amiloides e para visualizar depositos amiloides utilizando derivados de isoindolina
EP1284729A4 (en) 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US20030176454A1 (en) 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
BRPI0407913A (pt) 2003-02-27 2006-03-01 Hoffmann La Roche antagonistas receptores de ccr-3
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
BRPI0413540A (pt) 2003-08-14 2006-10-10 Hoffmann La Roche moduladores gabanérgicos
US7884112B2 (en) 2004-03-08 2011-02-08 Stuart Edward Bradley Pyrrolopyridine-2-carboxylic acid hydrazides
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
WO2006046575A1 (ja) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. シンナミド化合物の非晶質体
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2623317A1 (en) 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as ccr3 receptor liquids
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
EP1937767B1 (en) 2005-10-11 2013-05-22 Chemtura Corporation Diaromatic amines
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
EP2099798A1 (en) 2006-12-01 2009-09-16 Galapagos N.V. Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
JP2010513495A (ja) 2006-12-20 2010-04-30 シェーリング コーポレイション 新規なjnk阻害剤
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
US8252803B2 (en) 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
BRPI0811993A2 (pt) 2007-05-11 2014-11-18 Hoffmann La Roche " hetarilanilinas como moduladores para beta-amiloide ".
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
JP2010532354A (ja) 2007-06-29 2010-10-07 シェーリング コーポレイション γセクレターゼモジュレーター
CA2693138A1 (en) * 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
MX2010002674A (es) 2007-09-06 2010-03-25 Schering Corp Moduladores de gamma secretasa.
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
AU2008333865A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
EP2257541B1 (en) 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010054078A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
BRPI0921348A2 (pt) 2008-11-10 2019-09-24 Hoffmann La Roche moduladores heterocíclicos da gama secretase
EP2367817A4 (en) 2008-12-03 2012-05-09 Via Pharmaceuticals Inc INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE ENZYME
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
MX2011008335A (es) 2009-02-06 2011-09-06 Ortho Mcneil Janssen Pharm Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa.
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
US8754100B2 (en) 2009-02-26 2014-06-17 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
CA2751534A1 (en) 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US20110299830A1 (en) 2009-03-16 2011-12-08 Panasonic Corporation Application running device
WO2010126745A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS
WO2010145883A1 (en) 2009-05-07 2010-12-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
CA2778517A1 (en) 2009-07-15 2011-01-20 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
KR20120123677A (ko) 2010-01-15 2012-11-09 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 트리아졸 유도체
BR112013023984A2 (pt) 2011-03-24 2016-09-13 Cellzome Ltd derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物

Also Published As

Publication number Publication date
AU2010272578A1 (en) 2012-01-19
ZA201200285B (en) 2014-06-25
MX2012000763A (es) 2012-02-08
TW201109316A (en) 2011-03-16
ES2519565T3 (es) 2014-11-07
NZ597505A (en) 2013-05-31
WO2011006903A1 (en) 2011-01-20
EA201270166A1 (ru) 2012-06-29
SG177644A1 (en) 2012-03-29
EA021047B1 (ru) 2015-03-31
EP2454239A1 (en) 2012-05-23
AU2010272578B2 (en) 2015-03-05
JP2012532912A (ja) 2012-12-20
IL217491A (en) 2015-08-31
EP2454239B1 (en) 2014-08-13
JP2015129147A (ja) 2015-07-16
CA2778517A1 (en) 2011-01-20
CN102482227A (zh) 2012-05-30
BR112012000915A2 (pt) 2019-09-24
KR20120050450A (ko) 2012-05-18
IL217491A0 (en) 2012-02-29
US8946266B2 (en) 2015-02-03
US20120135981A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
AP2011006034A0 (en) Substituted triazole and imidazole derivatives as gamma secretase modulators.
AP2011005692A0 (en) Substituted bicyclic imidazole derivatives as gamma secretase modulators.
ZA201205240B (en) Novel substituted triazole derivatives as gamma secretase modulators
IL212497A0 (en) Heterocyclic gamma secretase modulators
ZA201108117B (en) Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
AP2011005779A0 (en) Novel susbstituted bicyclic heterocyclic compoundsas gamma secretase modulators.
IL206172A0 (en) Gamma secretase modulators
IL201960A0 (en) Gamma secretase modulators
ZA201003125B (en) Imidazole derivatives
HK1187605A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2
ME02455B (me) Derivati indazola supstituisanog sa benzodioksinilom
IL202315A0 (en) Gamma secretase modulators
IL209025A0 (en) Urea compounds as gamma secretase modulators
IL205148A0 (en) Novel imidazole derivatives
AP2011005725A0 (en) Lactams as beta secretase inhibitors.
IL207225A0 (en) Indazole derivatives
IL218696A0 (en) 2-oxo-1- pyrrolidinyl imidazothiadiazole derivatives
EP2341776A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
IL202316A0 (en) Gamma secretase modulators
IL205149A0 (en) Novel imidazole derivatives
GB0806745D0 (en) Novel imidazole derivatives
ZA201102049B (en) Substituted imidazole combinations
EP2403338A4 (en) IMIDAZOLE DERIVATIVES AS FAAH MODULATORS AND AS A FAAH CONTRASTANT
GB0904315D0 (en) Novel imidazole derivatives
ZA200908475B (en) Gamma secretase modulators